Safety and effectiveness of Rivaroxaban, Dabigatran and Apixaban in patients with non-valvular atrial fibrillation for stroke prophylaxis.

In our study, no major bleeding events were observed in the apixaban group, and the stroke rate was lower; however, these differences did not reach statistical significance. While low-dose DOAC use was common in the studies by Chan et al., standard dosing was predominantly used in our study.

also in 111,027 other papers